BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 8837142)

  • 21. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
    Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Solitary serum methotrexate level 36 hours post high-dose methotrexate: A safe, efficacious, and cost-effective strategy to monitor methotrexate toxicities in childhood leukemia in resource-limited centers.
    Khera S; Kapoor R; Pramanik SK
    Pediatr Blood Cancer; 2020 Jul; 67(7):e28387. PubMed ID: 32400952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A decrease in vitamin D levels is associated with methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.
    Oosterom N; Dirks NF; Heil SG; de Jonge R; Tissing WJE; Pieters R; van den Heuvel-Eibrink MM; Heijboer AC; Pluijm SMF
    Support Care Cancer; 2019 Jan; 27(1):183-190. PubMed ID: 29922939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
    Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Investigation on individualized adjustment of target range of high-dose methotrexate].
    Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
    Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The miR-1206 microRNA variant is associated with methotrexate-induced oral mucositis in pediatric acute lymphoblastic leukemia.
    Gutierrez-Camino A; Oosterom N; den Hoed MAH; Lopez-Lopez E; Martin-Guerrero I; Pluijm SMF; Pieters R; de Jonge R; Tissing WJE; Heil SG; García-Orad A; van den Heuvel-Eibrink MM
    Pharmacogenet Genomics; 2017 Aug; 27(8):303-306. PubMed ID: 28628559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole.
    Yang CH; Yang LJ; Jaing TH; Chan HL
    Int J Dermatol; 2000 Aug; 39(8):621-3. PubMed ID: 10971734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study.
    Schmidt D; Kristensen K; Schroeder H; Wehner PS; Rosthøj S; Heldrup J; Damsgaard L; Schmiegelow K; Mikkelsen TS
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27637. PubMed ID: 30835935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia.
    Liu Y; Yin Y; Sheng Q; Lu X; Wang F; Lin Z; Tian H; Xu A; Zhang J
    PLoS One; 2014; 9(1):e82681. PubMed ID: 24404132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy.
    Yanagimachi M; Goto H; Kaneko T; Naruto T; Sasaki K; Takeuchi M; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto S; Takahashi H; Mori M; Kai S; Yokota S
    Int J Hematol; 2013 Dec; 98(6):702-7. PubMed ID: 24241962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
    Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach.
    Odoul F; Le Guellec C; Lamagnère JP; Breilh D; Saux MC; Paintaud G; Autret-Leca E
    Fundam Clin Pharmacol; 1999; 13(5):595-604. PubMed ID: 10520733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum Creatinine Versus Plasma Methotrexate Levels to Predict Toxicities in Children Receiving High-dose Methotrexate.
    Tiwari P; Thomas MK; Pathania S; Dhawan D; Gupta YK; Vishnubhatla S; Bakhshi S
    Pediatr Hematol Oncol; 2015; 32(8):576-84. PubMed ID: 26558505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A single assessment of methotrexate levels at 42 hours permits safe administration and early discharge in children with lymphoblastic lymphoma and leukemia receiving high-dose methotrexate.
    Totadri S; Srinivasan HN; Joseph LL; Boddu D; Mathew LG; John R
    Pediatr Hematol Oncol; 2021 Aug; 38(5):434-443. PubMed ID: 33764242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.
    Oosterom N; Berrevoets M; den Hoed MAH; Zolk O; Hoerning S; Pluijm SMF; Pieters R; de Jonge R; Tissing WJE; van den Heuvel-Eibrink MM; Heil SG
    Pharmacogenet Genomics; 2018 Oct; 28(10):223-229. PubMed ID: 30222710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma.
    Nakano T; Kobayashi R; Matsushima S; Hori D; Yanagi M; Suzuki D; Kobayashi K
    Int J Hematol; 2021 May; 113(5):744-750. PubMed ID: 33389654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Late-onset delayed excretion of methotrexate.
    Pauley JL; Panetta JC; Schmidt J; Kornegay N; Relling MV; Pui CH
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):146-52. PubMed ID: 15148625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Adverse effects of methotrexate in the treatment of acute lymphoblastic leukemia in Uyghur and Han children].
    Hu WW; Nuriding H; Yan M
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 Nov; 14(11):852-5. PubMed ID: 23146734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral mucositis in childhood cancer patients receiving high-dose methotrexate: Prevalence, relationship with other toxicities and methotrexate elimination.
    Valer JB; Curra M; Gabriel AF; Schmidt TR; Ferreira MBC; Roesler R; Evangelista JMC; Martins MAT; Gregianin L; Martins MD
    Int J Paediatr Dent; 2021 Mar; 31(2):238-246. PubMed ID: 32815183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Correlation study of blood drug concentration and nephrotoxicity on high dose methotrexate therapy in suggestion of diagnosis and treatment of childhood acute lymphoblastic leukemia in the 4th revised edition].
    Cheng DH; Lu H; Zou XQ
    Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):771-774. PubMed ID: 29050116
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.